COST ANALYSIS OF PATIENTS WITH SQUAMOUS CELL CERVICAL CANCER STAGE IIB-IIIB WITH PACLITAXEL CISPLATIN CHEMOTHERAPY FROM THE SOCIETAL PERSPECTIVE

  • Ni Kd Rintan Listiani Ekayanti Department of Pharmacy Udayana University
  • Rini Noviyani Department of Pharmacy, Faculty of Math and Science, Udayana University
  • Sagung Chandra Yowani Department of Pharmacy, Faculty of Math and Science, Udayana University
  • Ketut Ariawati Departement of Pediatric, Faculty of Medicine, Udayana University, Bali, Indonesia
  • I Nyoman G. Budiana Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Bali, Indonesia
DOI: https://doi.org/10.24843/JPSA.2023.v05.i01.p05

Abstract

Background: The high prevalence of cervical cancer patients and the variety of necessary expenses needed causing financial hardship to both the patient and hospital. Furthermore, the disparity between the INA-CBGs rates and the costs of treatment incurred by hospitals and the limited information regarding the costs of cervical cancer undergoing cisplatin paclitaxel chemotherapy as viewed from a societal perspective were the reasons to conduct this research. Objective: The aim of this study was to determine the cost of squamous cell cervical cancer patients at stage IIB-IIB who received cisplatin paclitaxel chemotherapy from a social perspective. So in this study the difference in costs is used to calculate costs from a hospital perspective. Methods: This research was an observational study with a prospective incidence approach and consecutive sampling as the sampling method. This research was conducted from January to June 2017 at Sanglah General Hospital, Denpasar. Cost data from a societal perspective for six chemotherapy series were obtained from the Claim Guarantee Installation, Fund Mobility Section, interviews and filling in the logbook by patients and then calculated using the micro-costing method. Results: The results of this study obtained five patients who met the inclusion criteria. From the perspective of BPJS Kesehatan, the average cost of cervical cancer with paclitaxel cisplatin chemotherapy was IDR 24.703.470,00. From a hospital perspective, the average cost of cervical cancer with paclitaxel cisplatin chemotherapy was IDR 6.619.204,00., and from the perspective of patients and their families, the average burden of costs for cervical cancer with paclitaxel cisplatin chemotherapy was IDR 9.149.300,00. Conclusion: Cost analysis on five squamous cell cervical cancer patients with stage IIB-IIIB with six series of paclitaxel cisplatin chemotherapy viewed from the perspective of BPJS Kesehatan, hospital was IDR 24,703,470.00, IDR 6,619,204.00, and IDR 9,149,300.00, respectively.


Keywords: Cervical Cancer; Chemotherapy; Cost Analysis; Paclitaxel Cisplatin; Societal Perspective

Downloads

Download data is not yet available.
Published
2023-06-01
How to Cite
EKAYANTI, Ni Kd Rintan Listiani et al. COST ANALYSIS OF PATIENTS WITH SQUAMOUS CELL CERVICAL CANCER STAGE IIB-IIIB WITH PACLITAXEL CISPLATIN CHEMOTHERAPY FROM THE SOCIETAL PERSPECTIVE. Journal Pharmaceutical Science and Application, [S.l.], v. 5, n. 1, p. 34-44, june 2023. ISSN 2301-7708. Available at: <https://ojs.unud.ac.id/index.php/jpsa/article/view/99999>. Date accessed: 21 nov. 2024. doi: https://doi.org/10.24843/JPSA.2023.v05.i01.p05.
Citation Formats
Issue
Vol 5 No 1 (2023): Journal Pharmaceutical Science and Application (JPSA)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access).

 

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.